Literature DB >> 25263532

Treatment of esophageal motility disorders based on the chicago classification.

Carla Maradey-Romero1, Scott Gabbard, Ronnie Fass.   

Abstract

OPINION STATEMENT: The Chicago Classification divides esophageal motor disorders based on the recorded value of the integrated relaxation pressure (IRP). The first group includes those with an elevated mean IRP that is associated with peristaltic abnormalities such as achalasia and esophagogastric junction outflow obstruction. The second group includes those with a normal mean IRP that is associated with esophageal hypermotility disorders such as distal esophageal spasm, hypercontractile esophagus (jackhammer esophagus), and hypertensive peristalsis (nutcracker esophagus). The third group includes those with a normal mean IRP that is associated with esophageal hypomotility peristaltic abnormalities such as absent peristalsis, weak peristalsis with small or large breaks, and frequent failed peristalsis. The therapeutic options vary greatly between the different groups of esophageal motor disorders. In achalasia patients, potential treatment strategies comprise medical therapy (calcium channel blockers, nitrates, and phosphodiesterase 5 inhibitors), endoscopic procedures (botulinum toxin A injection, pneumatic dilation, or peroral endoscopic myotomy) or surgery (Heller myotomy). Patients with a normal IRP and esophageal hypermotility disorder are candidates for medical therapy (nitrates, calcium channel blockers, phosphodiesterase 5 inhibitors, cimetropium/ipratropium bromide, proton pump inhibitors, benzodiazepines, tricyclic antidepressants, trazodone, selective serotonin reuptake inhibitors, and serotonin-norepinephrine reuptake inhibitors), endoscopic procedures (botulinum toxin A injection and peroral endoscopic myotomy), or surgery (Heller myotomy). Lastly, in patients with a normal IRP and esophageal hypomotility disorder, treatment is primarily focused on controlling the presence of gastroesophageal reflux with proton pump inhibitors and lifestyle modifications (soft and liquid diet and eating in the upright position) to address patient's dysphagia.

Entities:  

Year:  2014        PMID: 25263532     DOI: 10.1007/s11938-014-0032-9

Source DB:  PubMed          Journal:  Curr Treat Options Gastroenterol        ISSN: 1092-8472


  120 in total

1.  Effects of previous treatment on results of laparoscopic Heller myotomy for achalasia.

Authors:  M G Patti; C V Feo; M Arcerito; M De Pinto; A Tamburini; U Diener; W Gantert; L W Way
Journal:  Dig Dis Sci       Date:  1999-11       Impact factor: 3.199

2.  Efficacy of venlafaxine for symptomatic relief in young adult patients with functional chest pain: a randomized, double-blind, placebo-controlled, crossover trial.

Authors:  Hyuk Lee; Jeong Hwan Kim; Byung-Hoon Min; Jun Haeng Lee; Hee Jung Son; Jae J Kim; Jong Chul Rhee; Young Ju Suh; Seonwoo Kim; Poong-Lyul Rhee
Journal:  Am J Gastroenterol       Date:  2010-03-23       Impact factor: 10.864

Review 3.  ACC/AHA expert consensus document. Use of sildenafil (Viagra) in patients with cardiovascular disease. American College of Cardiology/American Heart Association.

Authors:  M D Cheitlin; A M Hutter; R G Brindis; P Ganz; S Kaul; R O Russell; R M Zusman
Journal:  J Am Coll Cardiol       Date:  1999-01       Impact factor: 24.094

4.  Peroral endoscopic myotomy for the treatment of achalasia: an international prospective multicenter study.

Authors:  Daniel Von Renteln; Karl-Hermann Fuchs; Paul Fockens; Peter Bauerfeind; Melina C Vassiliou; Yuki B Werner; Gerald Fried; Wolfram Breithaupt; Henriette Heinrich; Albert J Bredenoord; Jan F Kersten; Tessa Verlaan; Michael Trevisonno; Thomas Rösch
Journal:  Gastroenterology       Date:  2013-05-09       Impact factor: 22.682

5.  Distal esophageal spasm in high-resolution esophageal pressure topography: defining clinical phenotypes.

Authors:  John E Pandolfino; Sabine Roman; Dustin Carlson; Daniel Luger; Kiran Bidari; Lubomyr Boris; Monika A Kwiatek; Peter J Kahrilas
Journal:  Gastroenterology       Date:  2011-05-06       Impact factor: 22.682

6.  Effects of sildenafil on esophageal motility of patients with idiopathic achalasia.

Authors:  M Bortolotti; C Mari; C Lopilato; G Porrazzo; M Miglioli
Journal:  Gastroenterology       Date:  2000-02       Impact factor: 22.682

7.  Treatment of symptomatic nonachalasia esophageal motor disorders with botulinum toxin injection at the lower esophageal sphincter.

Authors:  L S Miller; H P Parkman; T D Schiano; M J Cassidy; R B Ter; M A Dabezies; S Cohen; R S Fisher
Journal:  Dig Dis Sci       Date:  1996-10       Impact factor: 3.199

8.  A stepwise approach and early clinical experience in peroral endoscopic myotomy for the treatment of achalasia and esophageal motility disorders.

Authors:  Lee L Swanström; Erwin Rieder; Christy M Dunst
Journal:  J Am Coll Surg       Date:  2011-10-13       Impact factor: 6.113

Review 9.  Current therapies for achalasia: comparison and efficacy.

Authors:  M F Vaezi; J E Richter
Journal:  J Clin Gastroenterol       Date:  1998-07       Impact factor: 3.062

10.  An alternative method for mucosal flap closure during peroral endoscopic myotomy using an over-the-scope clipping device.

Authors:  P Saxena; Y H Chavez; A Kord Valeshabad; A N Kalloo; M A Khashab
Journal:  Endoscopy       Date:  2013-04-16       Impact factor: 10.093

View more
  7 in total

1.  Gastrointestinal Uses of Botulinum Toxin.

Authors:  Maria Cariati; Maria Michela Chiarello; Marco Cannistra'; Maria Antonietta Lerose; Giuseppe Brisinda
Journal:  Handb Exp Pharmacol       Date:  2021

Review 2.  [Esophageal motility disorders].

Authors:  M Müller; I Gockel
Journal:  Internist (Berl)       Date:  2015-06       Impact factor: 0.743

3.  Early clinical experience with the POEM procedure for achalasia.

Authors:  Dennis Hong; Radu Pescarus; Rana Khan; Luciano Ambrosini; Mehran Anvari; Margherita Cadeddu
Journal:  Can J Surg       Date:  2015-12       Impact factor: 2.089

4.  Pseudoachalasia: Still a Tough Clinical Challenge.

Authors:  Yi Jia; Richard W McCallum
Journal:  Am J Case Rep       Date:  2015-10-29

Review 5.  Treatment of gastrointestinal sphincters spasms with botulinum toxin A.

Authors:  Giuseppe Brisinda; Nicola Sivestrini; Giuseppe Bianco; Giorgio Maria
Journal:  Toxins (Basel)       Date:  2015-05-29       Impact factor: 4.546

6.  Gender, medication use and other factors associated with esophageal motility disorders in non-obstructive dysphagia.

Authors:  Afrin Kamal; Sampurna Shakya; Rocio Lopez; Prashanthi N Thota
Journal:  Gastroenterol Rep (Oxf)       Date:  2018-06-02

7.  Mosapride Improves Lower Esophageal Sphincter and Esophageal Body Function in Patients With Minor Disorders of Esophageal Peristalsis.

Authors:  Sung Eun Kim; Moo In Park; Seun Ja Park; Won Moon; Jae Hyun Kim; Kyoungwon Jung; Hye Jung Kwon; Gyung Mi Kim; Hee Kyoung Joo
Journal:  J Neurogastroenterol Motil       Date:  2020-04-30       Impact factor: 4.924

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.